Qube Research & Technologies (QRT)
RVNC

Qube Research & Technologies (QRT)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,328,525
Closed -$4.04M – 3985
2024
Q4 		$4.04M Sell
1,328,525
-562,736
-30% -$2.45M 0.01% 1596
2024
Q3 		$9.82M Buy
+1,891,261
New +$9.4M 0.01% 1056
2024
Q1 		– Sell
-503,874
Closed -$4.43M – 4961
2023
Q4 		$4.43M Buy
503,874
+389,624
+341% +$3.19M 0.01% 1110
2023
Q3 		$1.31M Sell
114,250
-24,347
-18% -$468K ﹤0.01% 1598
2023
Q2 		$3.51M Buy
138,597
+85,576
+161% +$2.67M 0.01% 824
2023
Q1 		$1.71M Sell
53,021
-88,859
-63% -$2.77M 0.01% 1075
2022
Q4 		$2.62M Buy
141,880
+113,211
+395% +$2.59M 0.01% 856
2022
Q3 		$774K Buy
+28,669
New +$582K ﹤0.01% 1296
2021
Q3 		– Sell
-23,435
Closed -$695K – 2891
2021
Q2 		$695K Buy
+23,435
New +$676K 0.01% 1110
2020
Q4 		– Sell
-14,353
Closed -$361K – 2279
2020
Q3 		$361K Buy
14,353
+1,236
+9% +$32.4K 0.01% 1165
2020
Q2 		$320K Buy
+13,117
New +$259K ﹤0.01% 1272

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RVNC Position: Q1 2025 in Review

Qube Research & Technologies (QRT) sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,328,525 shares — an estimated $4.04M sold.

Qube Research & Technologies (QRT) first reported a position in RVNC in Q2 2020 and held it in 11 quarters. The position peaked at $9.82M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Qube Research & Technologies (QRT) reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 1,328,525 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $4.04M.
  • Qube Research & Technologies (QRT) first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 11 quarters.
  • Qube Research & Technologies (QRT)'s Revance Therapeutics, Inc. position peaked at $9.82M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2025, filed 15 May 2025.